BioSpace News Archive

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.

The latest market analysis report published by Reports and Data, titled ‘Global Virtual Clinical Trial Market – Forecast to 2028,’ thoroughly examines the Virtual Clinical Trial industry to provide essential data & information for the targeted readers.

Rising incidence of various acute and chronic diseases, increasing need for advanced solutions for managing large patient data, and high focus on improving overall healthcare outcome are some key factors expected to drive global Population Health Management Solutions market growth.

Increasing number of surgeries across the globe, rapid adoption of advanced surgical instruments, and rising need for advanced maintaining and keeping a track of the instruments are expected to drive global Surgical Instrument Tracking Systems market growth.

Entos Pharmaceuticals, a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle nucleic acid delivery platform, announced the opening of its new 9,600 square foot research and development facility in the Torrey Pines community of San Diego, California.

Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says.

Phase 2 study completed enrollment ahead of schedule.

June 9 discussion will focus on eli-cel for the treatment of early active cerebral adrenoleukodystrophy in patients without a matched sibling donor and overall safety of lentiviral vector (LVV) gene therapy.

ScImage Inc., a leading provider of Enterprise Imaging solutions and DiA Imaging Analysis, a global leading provider of AI-based cardiac ultrasound software, announced today a commercial partnership to combine ScImage’s unique Cloud architecture with DiA’s AI-based automated cardiac ultrasound solution, LVivo Seamless™.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older in Switzerland.